This research demonstrates the effectiveness of a single-electron oxidation strategy for deuteration of alkyl halides, revealing new potential in drug development.
Deuterium labeling is extensively utilized across various scientific disciplines. The dehalogenative deuteration of organic halides offers a promising approach for achieving deuterium labeling. However, existing methods for dehalogenative deuteration primarily focus on sp2-hybridized aryl halides, while sp3-hybridized alkyl halides, especially bromides and chlorides, exhibit low reactivity and pose significant challenges for reduction. This limitation hampers the development of deuteration methodologies. In this study, a robust and versatile mechanochemical strategy is introduced for deuterating both activated and unactivated alkyl halides (X = Cl, Br, I), employing D2O as an economical deuterium source and electron donor, catalyzed by a piezoelectric material. Importantly, unlike previously mechanochemical piezoelectric catalysis reactions that are typically initiated by a single-electron reduction process, this transformation is triggered by a single-electron oxidation pathway. Employing this innovative technique, a variety of organic halides are successfully converted, including primary, secondary, and tertiary alkyl halides, into deuterated products with good yields and high deuterium incorporation, using only a chemically equivalent amount of D2O. The practical application of this green and efficient methodology is further demonstrated by late-stage deuteration on drug molecule analogs, underscoring its potential utility in pharmaceutical development.
No takes yet. Share an insight, caveat, or question.
Qu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: